Skip to content

Advancing the
Next Generation
of iPSC-derived NK Cell and Macrophage Immunotherapies

Leading the Legacy of the
Most Effective and Affordable Cell Therapies

We develop genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer (NK) and macrophage products that are intelligently designed for greater potency and persistence, overcoming the limitations of early cell therapies, for use in oncology and regenerative medicine.

An Experienced
Founding Team

Our early successes are a direct result of the co-founder’s leadership, tenure, and expertise in pushing the boundaries of scientific innovation. With our deep expertise in iPSC differentiation methods and genetic reprogramming, we strive to intelligently advance oncological and regenerative cell therapies by improving upon and overcoming the variety of limitations of earlier cell therapies.

Kleanthis G.
Xanthopoulos, Ph.D.

CO-FOUNDER & CEO

Dan S. Kaufman,
M.D., Ph.D.

CO-FOUNDER & CSO

Steven
Holtzman

CO-FOUNDER & DIRECTOR

William Sandborn,
M.D.

CO-FOUNDER & CMO

Investors

Boxer-Capital-400
BVF-400
Commodore-400
Cormorant-Asset-Management-400
Janus-Henderson-400
Logos-Capital-400
Kite-Capital-400
Wedbush-400
Stork-400

PARTNERS

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, BioGene is committed to expediting the development of a diverse pipeline of novel therapeutics through collaborations or their internal capabilities, with the aspirational goal of radically improving access to medicines for two billion more people by 2030. BeiGene is a headquarter-less company by design, with a growing global team of approximately 6,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com and follow them on Twitter at @BeiGeneGlobal.

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with commercial manufacturing operations in North America and Europe. Kite’s singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company. For more information on Kite, please visit www.kitepharma.com

Engineering Unlimited Lifesaving Therapies from A Single Cell

The induced pluripotent stem cell (iPSC)-derived allogeneic technology has opened profound improvements in immunotherapies. From a single genetically enhanced master cell, we create an unlimited homogenous bank of superior cells that are cryopreserved until needed for universal patient dosing. This off-the-shelf approach results in the safest and most sustainable, affordable, and accessible delivery of targeted immunotherapies to patients.